Literature DB >> 19343349

[Current diagnostic and therapy of light chain amyloidosis].

S O Schönland1, T Bochtler, A V Kristen, A D Ho, U Hegenbart.   

Abstract

Amyloidoses are protein-folding disorders in which soluble proteins are deposited as insoluble fibrillar aggregates due to a change in protein conformation. This might occur intra- or extracellularly, systemically or in a localized manner. The light chain type is the most common form of systemic amyloidoses and has the worst prognosis. The underlying disease is a monoclonal, mostly non-malignant plasma cell disorder. The causative treatment is the reduction of the amyloidogenic light chains with conventional or high-dose chemotherapy. Meanwhile, the"new drugs" used in multiple myeloma are also successfully applied. Early diagnosis is important to be able to treat patients effectively and to avoid further deterioration of organ function. Patients with newly diagnosed amyloidosis should be referred to a specialized center for consultation, diagnosis and treatment recommendation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19343349     DOI: 10.1007/s00292-009-1132-5

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  22 in total

1.  Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine.

Authors:  A R Bradwell; H D Carr-Smith; G P Mead; L X Tang; P J Showell; M T Drayson; R Drew
Journal:  Clin Chem       Date:  2001-04       Impact factor: 8.327

2.  The spectrum of localized amyloidosis: a case series of 20 patients and review of the literature.

Authors:  Michelle L Biewend; David M Menke; Kenneth T Calamia
Journal:  Amyloid       Date:  2006-09       Impact factor: 7.141

3.  Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis.

Authors:  Giovanni Palladini; Paola Russo; Mario Nuvolone; Francesca Lavatelli; Vittorio Perfetti; Laura Obici; Giampaolo Merlini
Journal:  Blood       Date:  2007-07-15       Impact factor: 22.113

4.  Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response.

Authors:  Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Suzanne R Hayman; Shaji K Kumar; Nelson Leung; Dennis A Gastineau
Journal:  Haematologica       Date:  2007-10       Impact factor: 9.941

5.  Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation.

Authors:  Stefan O Schönland; Henk Lokhorst; Agnes Buzyn; Veronique Leblond; Ute Hegenbart; Giuseppe Bandini; Andrew Campbell; Enric Carreras; Augustin Ferrant; Leanthe Grommisch; Peter Jacobs; Nicolaus Kröger; Giorgio La Nasa; Nigel Russell; Pierre Zachee; Hartmut Goldschmidt; Simona Iacobelli; Dietger Niederwieser; Gösta Gahrton
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

6.  High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.

Authors:  Jolanta B Perz; Stefan O Schonland; Michael Hundemer; Arnt V Kristen; Thomas J Dengler; Martin Zeier; Reinhold P Linke; Anthony D Ho; Hartmut Goldschmidt
Journal:  Br J Haematol       Date:  2004-12       Impact factor: 6.998

7.  Sjögren's syndrome and localized nodular cutaneous amyloidosis: coincidence or a distinct clinical entity?

Authors:  Jiska M Meijer; Stefan O Schonland; Giovanni Palladini; Giampaolo Merlini; Ute Hegenbart; Olga Ciocca; Vittorio Perfetti; Martha K Leijsma; Hendrika Bootsma; Bouke P C Hazenberg
Journal:  Arthritis Rheum       Date:  2008-07

8.  High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.

Authors:  Arnaud Jaccard; Philippe Moreau; Veronique Leblond; Xavier Leleu; Lotfi Benboubker; Olivier Hermine; Christian Recher; Bouchra Asli; Bruno Lioure; Bruno Royer; Fabrice Jardin; Frank Bridoux; Bernard Grosbois; Jérome Jaubert; Jean-Charles Piette; Pierre Ronco; Fabrice Quet; Michel Cogne; Jean-Paul Fermand
Journal:  N Engl J Med       Date:  2007-09-13       Impact factor: 91.245

9.  No regression of renal AL amyloid in monoclonal gammopathy after successful autologous blood stem cell transplantation and significant clinical improvement.

Authors:  Martin Zeier; Jolanta Perz; Reinhold P Linke; Ugo Donini; Rüdiger Waldherr; Konrad Andrassy; Anthony D Ho; Hartmut Goldschmidt
Journal:  Nephrol Dial Transplant       Date:  2003-12       Impact factor: 5.992

10.  Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability.

Authors:  Tilmann Bochtler; Ute Hegenbart; Friedrich W Cremer; Christiane Heiss; Axel Benner; Dirk Hose; Marion Moos; Jelena Bila; Claus R Bartram; Anthony D Ho; Hartmut Goldschmidt; Anna Jauch; Stefan O Schonland
Journal:  Blood       Date:  2008-02-27       Impact factor: 22.113

View more
  2 in total

1.  [Macroglossia in a 53-year-old man with muscle complaints].

Authors:  A Kolb-Mäurer; H Hamm; H Kneitz; M Mäurer
Journal:  Hautarzt       Date:  2013-04       Impact factor: 0.751

2.  Vertebral Osteomyelitis: A Mortality Analysis Comparing Surgical and Conservative Management.

Authors:  Spogmai Zadran; Peter Heide Pedersen; Søren Eiskjær
Journal:  Global Spine J       Date:  2019-07-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.